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Background: Accumulating evidence suggests that brachial plexopathy following head and neck cancer radiotherapy
may be underreported and that this toxicity is associated with a dose–response. Our purpose was to determine
whether the dose to the brachial plexus (BP) can be constrained, without compromising regional control.
Methods: The radiation plans of 324 patients with oropharyngeal carcinoma (OPC) treated with intensity-modulated
radiation therapy (IMRT) were reviewed. We identified 42 patients (13%) with gross nodal disease <1 cm from the BP.
Normal tissue constraints included a maximum dose of 66 Gy and a D05 of 60 Gy for the BP. These criteria took
precedence over planning target volume (PTV) coverage of nodal disease near the BP.
Results: There was only one regional failure in the vicinity of the BP, salvaged with neck dissection (ND) and regional
re-irradiation. There have been no reported episodes of brachial plexopathy to date.
Conclusions: In combined-modality therapy, including ND as salvage, regional control did not appear to be
compromised by constraining the dose to the BP. This approach may improve the therapeutic ratio by reducing the
long-term risk of brachial plexopathy.
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Brachial plexopathy is a potentially painful and debilitat-
ing complication of radiotherapy, characterized by sen-
sory changes and motor deficits [1]. The time to the
appearance of symptoms may vary significantly. Recent
modern studies have reported median times to onset of
symptoms ranging from 6.5 months to 4 years from the
completion of radiotherapy and ranges of 1.4 months to
26 years [2,3]. Once they develop, there may be a grad-
ual evolution of symptoms or a more rapid progression
with time, which may on occasion culminate in
complete loss of function of the affected arm [1,4].
Treatment options for these patients remain inadequate,
and prognosis is poor. Brachial plexopathy has been* Correspondence: mutter.robert@mayo.edu
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reproduction in any medium, provided the orassociated with greater cumulative radiation dose to the
brachial plexus (BP), radiotherapy fraction size, max-
imum dose, as well as the addition of chemotherapy and
neck dissection [1,2,4-6]. One group recently used a vali-
dated symptom questionnaire in order to screen a large
head-and-neck cancer population who had undergone
radiation therapy. Their goal was to identify predictors
of neuropathic symptoms thought to be related to brachial
plexopathy. Interestingly, 12% of patients reported neuro-
pathic symptoms, and there was a clear dose–response
relationship [6]. They concluded that dose to the brachial
plexus should be limited when possible. Suggested BP
normal tissue constraints on recent IMRT head and neck
protocols are shown in Table 1.
Intensity-modulated radiotherapy (IMRT) allows for
accurate targeting of disease while minimizing dose to
surrounding critical normal structures and has become
the standard treatment technique for the management
of oropharyngeal carcinoma and many other head andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Brachial plexus constraints on recent Radiation
Therapy Oncology Group intensity-modulated
radiotherapy head and neck cancer protocols
Protocol Brachial plexus constraint
RTOG 0022 None specified
RTOG 0025 None specified
RTOG 0522 Dmax ≤60 Gy
RTOG 0615 Dmax ≤66 Gy*
RTOG 0619 Dmax ≤66 Gy, D05 ≤60 Gy
RTOG 0912 Dmax ≤66 Gy to point source at least 0.03 cm3**
RTOG 1008 Dmax <60 Gy if no involved low neck nodes; <66 Gy
if low neck involved
RTOG 1016 None specified.
*The treating radiation oncologist has the option of prescribing an intermediate
dose of 63 Gy, PTV63 in the lower neck close to the brachial plexus.
**Suggested dose limit that should not compromise tumor coverage.
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cancers are treated definitively with IMRT, the planning
target volume (PTV) encompassing gross primary and
nodal disease is generally prescribed a dose of 70 Gy. If
lymphadenopathy is present in proximity of the BP, how-
ever, it is often difficult to constrain the dose to the BP
to meet normal tissue tolerance guidelines without at
least some compromise of PTV coverage.
In the context of multi-modality therapy for head and
neck cancers, including chemotherapy and neck dissec-
tion as salvage, IMRT treatment-planning guidelines
were adopted at Memorial Sloan-Kettering Cancer
Center in 2005 with the goal of reducing the risk of
brachial plexopathy. These allowed for less than 100%
coverage of the PTV in the low neck with the 70Gy
isodose line to ensure adherence to BP normal tissue
constraints of a maximum point dose (Dmax) of
65–66 Gy and a dose received by 5% of the tissue (D05)
of 60 Gy. We recently reviewed the treatment plans of
patients with squamous cell carcinoma of the orophar-
ynx who underwent IMRT at our center. Our purpose
was to determine whether these brachial plexus con-
straints impacted regional control.
Materials and methods
Patients/evaluation
Between January 2005 and April 2009, 324 patients with
histologically confirmed squamous cell carcinoma of the
oropharynx underwent definitive IMRT at our center.
From this group of 324 patients definitively treated with
IMRT after Institutional Review Board Approval we
identified 42 patients (13%) who had clinically or radio-
graphically positive gross nodal disease <1 cm from the
BP. These 42 patients were the subjects of this study.
January 2005 was chosen as a cut-off because it was at
that time that we began contouring and constraining the
BP for all patients treated with IMRT for head and neckcancer at our institution. This retrospective analysis was
approved by our Institutional Review Board.
Pretreatment evaluation included a complete history
and physical examination, flexible fiberoptic endoscopic
examination, complete blood counts, liver function tests,
chest X-ray, and dental evaluation, as well as magnetic
resonance imaging and/or computed tomography (CT)
scans of the head-and-neck region. CT scans of the chest
and abdomen, and positron emission tomography (PET)
scans were also obtained for most patients before the
start of treatment.
Treatment
Our treatment-planning techniques have previously been
described [7-9]. To account for setup error, the PTV70
was defined to encompass the gross primary and neck
disease plus margin (0.3-0.5 cm), the PTV59.4 was
defined as the high-risk subclinical disease plus margin
(0.3-0.5 cm), and the PTV54 was defined as the low-risk
subclinical disease plus margin (0.3 cm). We frequently
use a split-field technique for cancers of the oropharynx
when lymph nodes are not situated near the larynx, in
order to reduce the dose to that structure. All 42
patients reported here, however, had clinically a dose-
painting whole-neck IMRT technique [8].
Platinum-based chemotherapy was administered to
31 of the 42 patients (74%). Concurrent single-agent
cisplatin was the primary choice of chemotherapeutic
agent, consisting of a planned two to three cycles
(100 mg/m2) of cisplatin on days 1, 22, and 43. Eleven
(26%) received cetuximab. Routine planned neck dissec-
tions were not undertaken. Rather, a PET/CT scan was
typically performed 3 months after the completion of
radiotherapy and neck dissection was reserved for
patients with less than a complete response on imaging
or clinical examination. Location of dissected lymph
nodes was determined prospectively based on pathology
reports.
Constraining the brachial plexus
The BP was contoured for all patients prior to treatment
using a modified version of the Radiation Therapy
Oncology Group guidelines, with the most superior
extent of the structure at the level of the cricoid cartilage.
Normal tissue constraints adhered to included a Dmax of
66 Gy and a D05 of 60 Gy for the BP. Gross tumor volume
coverage was generally prioritized. However, the BP dose
volume criteria routinely took precedence over PTV
coverage near the BP. In order to study the dosimetric im-
pact of the BP constraints on PTV coverage, we defined
PTVBP70 as the portion of the PTV prescribed 70 Gy from
6 mm superior to 6 mm inferior of the ipsilateral BP. The
6 mm distance was chosen because PTV coverage outside
of this range would not be expected to be significantly
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occurring within or adjacent to the PTVBP70 were
presumed to have been potentially caused by the BP dose
constraint. Dose volume histograms were created for all
42 patients and dose volume parameters for the BP and
PTVBP70 were analyzed. Thirteen patients had bilateral
gross nodal disease within 1 cm of the BP. The dose
volume parameters for both the BP and PTVBP70 were
analyzed independently in these patients.
Follow-up
Patients were evaluated weekly during RT. After the
completion of radiation, patients were evaluated every
2–3 months for the first 2 years and every 4–6 months
thereafter. All All patients, including those who devel-
oped distant metastases, continued to be monitored
closely with regular physical exams, flexible fiberoptic
endoscopy, and radiographical studies to assess for
locoregional recurrence and symptoms of brachial
plexopathy. Human papillomavirus (HPV) status was
unavailable for patients on this study, but smoking sta-
tus, including median number of pack-years, is reported.
Statistical methods
The cumulative incidence function was used to describe
local recurrence, regional failure, and distant metastasis.
Death without recurrence was regarded as a competing
risk [10]. The time to recurrence was defined as the time
(in months) elapsed from the start of radiation to the
date of recurrence, death, or last follow-up. The Kaplan-
Meier method was used to describe overall survival [11].
Results
Characteristics of the 42 patients are summarized in
Table 2. The primary site was located in the base of
tongue in 69% and in the tonsil in 31%. Seventy-one per-
cent of patients were greater than 55 years old. Patients
in this study had low neck disease involvement in prox-
imity of the BP, and therefore relatively advanced-stage
disease compared to all patients presenting with oropha-
ryngeal carcinoma [12,13]. Forty-one of 42 patients
(97.6%) were AJCC stage IV, including 6 patients (14.3%)
with lymph nodes greater than 6 cm in maximum
diameter (N3).
Dose volume parameters of the BP and PTVBP70 for
the entire cohort are displayed in Table 3. For the
PTVBP70, the median D95 was 66.7 Gy and the median
minimum point dose (Dmin) was 58.7 Gy. For the BP,
the median Dmax was 63.4 Gy and the median D05 was
59.1 Gy. Just one patient in this study had both a BP
Dmax and D05 greater than 65 Gy and 60 Gy, respect-
ively. The radiation plans with corresponding isodose
lines for two representative patients are displayed in
Figure 1A and Figure 1B.Treatment outcomes
The median follow-up time was 35 months (range, 1–69).
Of the 42 patients, 8 underwent post-RT neck dissection
due to clinical or radiograph evidence of residual disease
following RT. For the PTVBP70 of these 8 patients, the me-
dian D95 was 67.4 Gy and the median Dmin was 59.4 Gy.
Histologic evidence of residual cancer was identified in 4
of these 8 patients. In one of the 4 patients, a single level 2
node contained viable tumor. In three patients, multiple
lymph nodes from the upper as well as the lower neck
contained viable tumor.
To date, there have been six regional recurrences. The
cumulative incidence of regional failure was 14% (95% CI
0.04- 0.25, Figure 2). For the PTVBP70 of these 6 patients,
the median D95 was 67.96 Gy and the median Dmin was
59.2 Gy, demonstrating slightly greater PTV coverage than
the median for the entire cohort. Review of pre- and post-
treatment imaging, operative notes, and pathology reports
demonstrated that just one isolated regional failure
occurred close to the PTVBP70 This patient presented
with a >10 cm level 3 node invading the skin. Following
chemoradiation, there was residual hypermetabolic activ-
ity in the periphery of the mass, and a planned neck dis-
section was performed. Pathology demonstrated a cystic
nodule of squamous cell carcinoma that was mostly nec-
rotic (<1% viable tumor cells present). All 28 other ex-
cised lymph nodes were negative. There was concern at
surgery for possible unresectable residual disease at the
carotid bulb which in this patient was above the brachial
plexus at the level of the 4th cervical vertebral body.
Therefore regional re-irradiation was administered post-
operatively. The patient developed evidence of distant
metastases 2 months following the completion of re-
irradiation and eventually succumbed from his disease
with disease locoregionally controlled. The D95 and Dmin
of the PTVBP70 for that patient were 62.3 and 51.6 Gy,
respectively. The other 5 regional failures in the study
included: Patient 1) A new contralateral out-of-field level
5 nodal neck failure in a previously node-negative hemi-
neck; Patient 2) A new ipsilateral high neck lymph node at
level II; Patients 3 and 4) Local recurrences with an
adjacent regional node in the high level II neck; 5) Local
recurrence and regional disease in level II and level IV.
The median number of pack-years smoked for the 6
patients with regional failures was 13. One of the six
patients was a never smoker, and 4 had a greater than
10 pack-year smoking history. Due to the small number
of events, we could not determine whether smoking
status was associated with a higher likelihood of regional
recurrence.
The cumulative incidence of local recurrence and dis-
tant metastasis were 10% (95% confidence interval [CI]
0.005-0.19, Figure 3A), and 29% (95% CI 0.15-0.43,
Figure 3B), respectively. The 3-year Kaplan-Meier estimated
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Abbreviations: AJCC American Joint Committee on Cancer, 5-FU 5-fluorouracil,
KPS Karnofsky performance status.
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Figure 3C). There have been no reported episodes of
brachial plexopathy to date.Discussion
To reduce the risk of the potentially debilitating late
effect of brachial plexopathy, BP dose constraints for
head and neck cancer IMRT treatment planning were
adopted at our institution that took precedence over
PTV coverage in the vicinity of the BP. The cohort of
patients with oropharayngeal squamous cell carcinoma
examined here all had lymphadenopathy extending into
levels III or IV of the neck, where there was risk of over-
lap with the brachial plexus. Therefore, they had more
advanced disease and more adverse prognostic features
than seen in recent reports and clinical trials for this dis-
ease [9,12,14]. For example, the rates of local failure and
distant metastases in our updated experience treating
patients with oropharyngeal carcinoma with IMRT were
5.4% and 12.5%, compared to 10% and 29% in the subset
reported here [13]. Despite these adverse features, just
one patient experienced an isolated regional recurrence
in proximity of the BP. This patient had a level III
node >10 cm in maximal diameter, invading into the skin.
At the time of neck dissection for residual tumor, there
was concern of persistent disease at the carotid bulb
which was not amenable to resection. The carotid bulb is
well above the C5 nerve root of the BP. Therefore, it isTable 3 Dose volume parameters
Parameter Median dose Gy (SD)
PTVBP70
D95 66.7 (6.4)
Minimum dose 58.7 (8.5)
Mean dose 71.9 (4.0)
D05 75.2 (5.1)
Maximum dose 76.9 (2.5)
Brachial plexus
Maximum dose 63.4 (4.1)
D05 59.1 (4.8)
Mean dose 52.8 (11.9)
A B
Figure 1 A. and B. CT slices through the low neck at the level of the brachial plexus along with corresponding dose-volume histograms in
two representative patients demonstrating constraining of the brachial plexus at the expense of the immediately adjacent gross nodal disease
PTV coverage.




















Figure 2 Cumulative incidence of regional recurrence.
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treatment outcome, although we cannot exclude that pos-
sibility. Ultimately, local control was established with a
course of postoperative re-irradiation. Four other patients
had regional recurrences on the ipsilateral side of the
constrained brachial plexus, but as described above, these
tended to be in the high neck and associated with local
recurrence at the primary. These patterns of recurrence
suggest that tumor biology, rather than brachial plexus
dose constraints, were likely responsible for the clinical
outcomes and that the treatment approach we adopted,
aimed at reducing the long-term risk of brachial
plexopathy, may ultimately improve the therapeutic
ratio.
Indeed, all 324 patients treated with IMRT for oropha-
ryngeal carcinoma at our institution were spared high
doses to the BP during the time period of this study.
This is particularly important as recent evidence has
emerged, more clearly establishing a dose–response






























































Figure 3 Cumulative incidence of local recurrence (A), distant metastasis (B), and Kaplan-Meier estimates of overall survival (C).
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One report in head and neck cancer patients following
RT suggested that the incidence of patient-reported BP-
associated neuropathies may be as high as 22% with
long-term follow-up. In that study, Chen et al. demon-
strated that radiation maximum dose to the BP was pre-
dictive of symptoms. They noted a significantly higher
number of patients with symptoms who received doses
of >70 Gy, suggesting a threshold effect [2,6]. Moreover,
each Gy increase in maximum dose was associated with
1.39 times greater odds of developing symptoms. In an-
other modern study of lung cancer patients treated with
definitive chemoradiation, receipt of a median brachial
plexus dose of >69 Gy and a maximum dose of >75 Gy to
2 cm3 were independent predictors of brachial plexopathy.The median follow-up time in our study was 35 months;
therefore, more time is required to determine the true
long-term risk of brachial plexopathy for this cohort of
patients where careful attention was paid to limiting the
dose to the BP [6]. Moreover, it is possible that a more
sensitive screening tool may better identify patients with
neuropathic symptoms that could potentially be attribut-
able to RT. To date, however, it is re-assuring that by
limiting a small volume of the BP to doses approaching
65–66 Gy, the incidence of brachial plexopathy in our
patients, closely followed in a multimodality setting, has
been low. This finding is consistent with these studies as
well as consensus guidelines [2,6,15].
The clinical decision balancing adequate PTV coverage
in the low neck with risk of brachial plexopathy is
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not unlike other clinical sites such as the central nervous
system, where protection of organs at risk such as the
optic chiasm or brainstem may impact PTV coverage.
Over 10% of all patients that presented to our institution
who underwent definitive radiation for oropharyngeal
squamous cell carcinoma had gross disease less than
1 cm from the BP. In another study, an estimated 20%
of patients with head and neck cancer treated with
IMRT had BP maximum point doses of >66 Gy [16]. In
addition, there is accumulating evidence of a rise in inci-
dence of oropharyngeal cancer in the United States and
Western Europe that is associated with an increase in
human papillomavirus (HPV)-associated cancers [17,18].
HPV-related oropharyngeal carcinomas are associated
with younger age at diagnosis [4,14]. Moreover, HPV
positivity is an independent predictor of improved over-
all survival [14,19]. Therefore, with patients experiencing
longer overall survival rates in this new era of viral-
induced carcinoma, efforts to reduce the dose to normal
tissue structures, like the brachial plexus, will be of
greater importance to limit risks of brachial plexopathy
and other late effects of therapy.
One limitation of our study is the lack of tumor HPV
status, which has been shown to be associated with
improved progression-free and overall survival in
oropharyngeal squamous cell carcinoma [14,20]. We did,
however, have data on tobacco smoking history, which is
inversely correlated with HPV status and has also been
independently associated with progression-free and over-
all survival. Due to the small number of recurrences,
however, we are unable to draw meaningful conclusions
on the impact of smoking status on regional control, let
alone control of disease in the vicinity of the BP. We
presently continue to apply the same BP constraints for
both HPV positive and and HPV negative patients seen
in our clinic.
At the Radiation Therapy Oncology Group (RTOG),
BP constraints have recently been incorporated into
IMRT head and neck cancer protocols (Table 1). Never-
theless, there remains some variation among protocols
and controversy about the appropriate treatment ap-
proach when disease involves the low neck. For example,
on RTOG 0615 for nasopharyngeal carcinoma, the BP
dose constraint is a maximum dose ≤66 Gy. On that
protocol, the treating radiation oncologist has the option
of prescribing an intermediate dose of 63 Gy in the
lower neck close to the BP [21]. For RTOG 0912 for
anaplastic thyroid carcinoma, BP constraints include a
BP maximum dose ≤66 Gy to a point source at least
0.03 cm3. However, RTOG 0912 specifies that this
“suggested dose limit” should not compromise tumor
coverage [22]. This is most likely due to the low life
expectancy of anaplastic thyroid cancer. For RTOG1016, the phase 3 trial of radiotherapy plus cetuximab
versus chemoradiotherapy in HPV-associated orophar-
ynx cancer, the BP is not defined as a normal tissue/
organ at risk [23]. Notably, the dose specification for low
neck nodes on that study is 60 Gy in 30 fractions. Our
results may provide some re-assurance to clinicians
enrolling patients on these and future studies that BP
constraints similar to those used in our study, will not
be expected to impact regional control.
It is noteworthy that no patients underwent adaptive
radiotherapy with replanning during the course of
treatment to account for anatomical changes, such as a
reduction in volume of neck lymphadenopathy. It is
possible that, in some patients, the dose to the PTV in
proximity of the BP was actually greater than what was
calculated from the original treatment plan as a result of
shrinkage of gross disease away from the BP and into
the higher-dose region of the PTV. In addition, all pa-
tients in this study received concurrent chemoradiation,
the majority of which was platinum based. Cisplatin has
been perhaps the most widely used chemotherapeutic
agent in combination with radiation. The biological basis
of radiation sensitization from platinum is evolving but
the most widely believed explanation is through inhib-
ition of sublethal damage repair [24]. We have previ-
ously reported inferior locoregional control with
concurrent cetuximab-based chemoradiation compared
with cisplatin [25]. We would therefore caution that our
data may not imply the safety of any compromise of
PTV coverage to meet BP dose constraints in patients
not receiving concurrent cisplatin-based chemotherapy.
Conclusion
In conclusion, in the context of combined-modality ther-
apy, including ND as salvage, regional control did not
appear to be compromised by constraining the dose to
the BP. We expect that attention to these normal tissue
dose-volume parameters will ultimately reduce the risk
of brachial plexopathy long-term. Our findings suggest
that when multimodality therapy is utilized to treat
OPC, BP constraints resembling those adopted at our
institution are safe. Furthermore, our study provides
data to justify constraining the BP in present and future
IMRT protocols for OPC. Close attention to sites of
recurrence are warranted on these prospective studies,
however, to confirm the findings reported here.
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